Nanoparticle-based celecoxib and plumbagin for the synergistic treatment of melanoma

Molecular Cancer Therapeutics

Volumn 16, Issue 3, 2017, Pages 440-452

  Gowda, Raghavendra ^a,b   Kardos, Gregory ^a   Sharma, Arati ^a   Singh, Sanjay ^a   Robertson, Gavin P ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CELECOXIB; CELEPLUM 777; CYCLOOXYGENASE 2; LIPOSOME; NANOLIPOSOME; NANOPARTICLE; PLUMBAGIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; NAPHTHOQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG FORMULATION; DRUG SCREENING; GENETICS; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELECOXIB; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DRUG COMPOUNDING; DRUG STABILITY; DRUG SYNERGISM; FEMALE; HUMANS; LIPOSOMES; MELANOMA; MICE; NANOPARTICLES; NAPHTHOQUINONES; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85014671376     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0285     Document Type: Article

References (69)

1. Haarberg HE, Smalley KS. Resistance to Raf inhibition in cancer. Drug Discov Today Technol 2014;11:27-32.
2. Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, et al. Genotype-selective combination therapies for melanoma identified by high-Throughput drug screening. Cancer Discov 2013;3:52-67.
3. Dahan A, Miller JM. The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs. AAPS J 2012;14:244-51.
4. Buckley ST, Frank KJ, Fricker G, Brandl M. Biopharmaceutical classification of poorly soluble drugs with respect to enabling formulations. Eur J Pharm Sci 2013;50:8-16.
5. Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 2009;8:111-28.
6. Brys AK, Gowda R, Loriaux DB, Robertson GP, Mosca PJ. Nanotechnologybased strategies for combating toxicity and resistance in melanoma therapy. Biotechnol Adv 2016;34:565-77.
7. Gowda R, Jones NR, Banerjee S, Robertson GP. Use of nanotechnology to develop multi-drug inhibitors for cancer therapy. JNanomedNanotechnol 2013;4:184.
8. Hawk ET, Viner JL, Dannenberg A, DuBois RN. COX-2 in cancer-A player that's defining the rules. J Natl Cancer Inst 2002;94:545-6.
9. Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy. Pharmacol Rep 2010;62:233-44.
10. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: Evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000;86:667-71.
11. Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP. Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma. Mol Cancer Ther 2013;12:3-15.
12. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30:377-86.
13. Greene ER, Huang S, Serhan CN, Panigrahy D. Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat 2011;96:27-36.
14. Nachat-Kappes R, Pinel A, Combe K, Lamas B, Farges MC, Rossary A, et al. Effects of enriched environment on COX-2, leptin and eicosanoids in a mouse model of breast cancer. PLoS One 2012;7:e51525.
15. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000;38:225-42.
16. Schonthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs 2008;17:197-208.
17. Hafeez BB, Zhong W, Fischer JW, Mustafa A, Shi X, Meske L, et al. Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1, 4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3Mluciferase cells in an orthotopic xenograft mouse model. Mol Oncol 2013;7:428-39.
18. Gomathinayagam R, Sowmyalakshmi S, Mardhatillah F, Kumar R, Akbarsha MA, Damodaran C. Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. Anticancer Res 2008; 28:785-92.
19. Sand JM, BinHafeez B, Jamal MS, Witkowsky O, Siebers EM, Fischer J, et al. Plumbagin (5-hydroxy-2-methyl-1, 4-naphthoquinone), isolated from Plumbago zeylanica, inhibits ultraviolet radiation-induced development of squamous cell carcinomas. Carcinogenesis 2012;33:184-90.
20. Zhang XQ, Yang CY, Rao XF, Xiong JP. Plumbagin shows anti-cancer activity in human breast cancer cells by the upregulation of p53 and p21 and suppression of G1 cell cycle regulators. Eur J Gynaecol Oncol 2016;37:30-5.
21. Hafeez BB, Fischer JW, Singh A, Zhong W, Mustafa A, Meske L, et al. Plumbagin inhibits prostate carcinogenesis in intact and castrated PTEN knockout mice via targeting PKCepsilon, Stat3, and epithelial-To-mesenchymal transition markers. Cancer Prev Res 2015;8:375-86.
22. Yan W, Tu B, Liu YY, Wang TY, Qiao H, Zhai ZJ, et al. Suppressive effects of plumbagin on invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and down-regulation of inflammatory cytokine expressions. Bone Res 2013;1:362-70.
23. Hafeez BB, Jamal MS, Fischer JW, Mustafa A, Verma AK. Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-kB signaling pathways. Int J Cancer 2012;131:2175-86.
24. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005;24:315-27.
25. Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T. COX-2 expression in malignant melanoma: A novel prognostic marker? Melanoma Res 2009; 19:8-16.
26. Montaguti P, Melloni E, Cavalletti E. Acute intravenous toxicity of dimethyl sulfoxide, polyethylene glycol 400, dimethylformamide, absolute ethanol, and benzyl alcohol in inbred mouse strains. Arzneimittelforschung 1994;44:566-70.
27. Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer 1997;71:103-7.
28. Gowda R, Madhunapantula SV, Sharma A, Kuzu OF, Robertson GP. Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. Mol Cancer Ther 2014;13:2328-40.
29. Kuzu OF, Gowda R, Sharma A, Robertson GP. Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. Mol Cancer Ther 2014;13:1690-703.
30. Gowda R, Madhunapantula SV, Kuzu OF, Sharma A, Robertson GP. Targeting multiple key signaling pathways in melanoma using leelamine. Mol Cancer Ther 2014;13:1679-89.
31. Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP. Seleniumcontaining histone deacetylase inhibitors for melanoma management. Cancer Biol Ther 2012;13:756-65.
32. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
33. Ashton JC. Drug combination studies and their synergy quantification using the Chou-Talalay method-letter. Cancer Res 2015;75:2400.
34. Panwar P, Pandey B, Lakhera PC, Singh KP. Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomed 2010;5:101-8.
35. Zheng S, Chang S, Lu J, Chen Z, Xie L, Nie Y, et al. Characterization of 9- nitrocamptothecin liposomes: Anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo. PLoS One 2011;6:e21064.
36. Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP. Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res 2012;25:259-74.
37. Sharma A, Madhunapantula SV, Gowda R, Berg A, Neves RI, Robertson GP. Identification of aurora kinase B and WEE1 as downstream targets of (V600E)B-RAF in melanoma. Am J Pathol 2013;182:1151-62.
38. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003;63:2881-90.
39. Rodrigues SV, Viana LM, Baumann W. UV/Vis spectra and solubility of some naphthoquinones, and the extraction behavior of plumbagin from Plumbago scandens roots in supercritical CO2. Anal Bioanal Chem 2006;385:895-900.
40. Alavijeh MS, Palmer AM. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines. IDrugs 2004;7:755-63.
41. Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, et al. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res 2009;15:1674-85.
42. Munkarah AR, Genhai Z, Morris R, Baker VV, Deppe G, Diamond MP, et al. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol 2003;88:429-33.
43. Hinz B, Ramer R, Eichele K, Weinzierl U, Brune K. Up-regulation of cyclooxygenase-2 expression is involved in R()-methanandamideinduced apoptotic death of human neuroglioma cells. Mol Pharmacol 2004;66:1643-51.
44. Na HK, Inoue H, Surh YJ. ET-18-O-CH3-induced apoptosis is causally linked to COX-2 upregulation in H-ras transformed human breast epithelial cells. FEBS Lett 2005;579:6279-87.
45. Elrod HA, Yue P, Khuri FR, Sun SY. Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism. Mol Cancer Ther 2009;8:2575-85.
46. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer 2012;12:349-61.
47. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. Eur J Cancer 2016;53:125-34.
48. Solit D, Sawyers CL. Drug discovery: how melanomas bypass new therapy. Nature 2010;468:902-3.
49. Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, et al. Pathways and therapeutic targets in melanoma. Oncotarget 2014;5:1701-52.
50. Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, Reynolds J, Prina-Mello A. Nanomedicine applied to translational oncology: A future perspective on cancer treatment. Nanomedicine 2016;12:81-103.
51. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60.
52. Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: An emerging approach for cancer therapy. Drug Discov Today 2012;17:1044-52.
53. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 2012;6:155-76.
54. DiStefano V, Klahn JJ. Observations on the pharmacology and hemolytic activity of dimethyl sulfoxide. Toxicol Appl Pharmacol 1965;7:660-6.
55. Hu CM, Aryal S, Zhang L. Nanoparticle-Assisted combination therapies for effective cancer treatment. Ther Deliv 2010;1:323-34.
56. Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol 2010;596: 467-88.
57. Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, et al. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res 2008;68:7638-49.
58. Liu F, Cao J, Wu J, Sullivan K, Shen J, Ryu B, et al. Stat3-Targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol 2013;133:2041-9.
59. Garrido C, Paco L, Romero I, Berruguilla E, Stefansky J, Collado A, et al. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis 2012;33:687-93.
60. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-47.
61. Yang CL, Liu YY, Ma YG, Xue YX, Liu DG, Ren Y, et al. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS One 2012;7:e37960.
62. Lakshmanan I, Ponnusamy MP, Das S, Chakraborty S, Haridas D, Mukhopadhyay P, et al. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-Apoptosis in breast cancer cells. Oncogene 2012;31:805-17.
63. Dai QS, Liu W, Wang XB, Lu N, Gong DD, Kong LY, et al. NCPMF-60 induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Anti-cancer Drugs 2011;22:46-57.
64. Horiuchi K, Umetani M, Minami T, Okayama H, Takada S, Yamamoto M, et al. Wilms' tumor 1-Associating protein regulates G2/M transition through stabilization of cyclin A2 mRNA. Proc Natl Acad Sci U S A 2006;103:17278-83.
65. Madhunapantula SV, Mosca PJ, Robertson GP. The Akt signaling pathway: An emerging therapeutic target in malignant melanoma. Cancer Biol Ther 2011;12:1032-49.
66. Madhunapantula SV, Robertson GP. Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res 2008;68:5-8.
67. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008;18:254-67.
68. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, et al. Activation of stat3 in humanmelanoma promotes brainmetastasis. Cancer Res 2006;66:3188-96.
69. Crawford S. Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front Pharmacol 2013;4:68.